Apple (AAPL) iPhone X ramp remains subdued - Mizuho

Get Alerts AAPL Hot Sheet
Rating Summary:
44 Buy, 19 Hold, 4 Sell
Rating Trend:

Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - November 14, 2017 11:03 AM EST)
(updated to expand analyst comments)
Mizuho Securities analyst Abhey Lamba said the Apple (NASDAQ: AAPL) iPhone X ramp remains subdued.
Lamba notes the firm's Japan team recently conducted field checks across the supply chain to gauge near-term iPhone procurement trends. iPhone X production estimates move lower by around 8mm units for CY17 on the back of slower-than-anticipated yield improvement.
In particular, the 3D-sensing module remains the bottleneck for the X, with yield improving on OLED panels, Lamba commented.
For the full-year, downside to X is partially offset by better 8+ volumes (relative to the iPhone 8) given the marginal price difference.
The analyst said in aggregate, total production for the year moves down about 1% from prior forecast of 226mm units.
"In our view, the street largely expects this and potentially better sell-through of other products could support mgmt's robust implied iPhone unit guide of around 77-80mm for DecQ," Lamba commented. "However, given the sustained n-t mix shift, ASPs could be impacted (recall that SepQ ASPs of $618 came in below consensus of $638)."
The firm maintained a Neutral and price target of $160.00
For an analyst ratings summary and ratings history on Apple click here. For more ratings news on Apple click here.
Shares of Apple closed at $173.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- These 7 Mega-cap and Large-cap Tech Stocks are Under-owned by Major Institutional Investors - Morgan Stanley
- Northland Capital Markets Starts Generac Holdings (GNRC) at Outperform, Likes Attractive Positioning for Energy Transition
- "Weakness is Buying Opportunity, Clinical Programs Remain Underappreciated by Investors" - Arcutis Biotherapeutics (ARQT) Defended at Mizuho Securities, Buy Rating and $57 Price Target Reiterated
Create E-mail Alert Related Categories
Analyst Comments, Hot Comments, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!